Thompson, Ph.D., Simon M. Petersen-Jones, D.Veterinarian.Med., Ph.D., Michel Michaelides, M.D., F.R.C.Ophth., L. Ingeborgh van den Born, M.D., Ph.D., Andrew Stockman, Ph.D., Alexander J. Smith, Ph.D., Gary Rubin, Ph.D., and Robin R. Ali, Ph.D. The encoded retinoid isomerase converts all-trans retinyl esters to 11-cis retinal for the regeneration of visible pigment after contact with light. RPE65 deficiency causes photoreceptor-cell dysfunction and impaired eyesight from birth. The function of cone photoreceptor cells, which mediate eyesight in daylight, is relatively preserved in childhood because cones get access to an substitute source of 11-cis retinal.2 However, progressive degeneration of both rod and cone photoreceptor cells, in association with regional accumulation of toxic retinyl esters,3 results in severe sight impairment by early adulthood.The world-wide ion channel medication market is estimated to be well worth USD 12 billion[1]. The measurement of the electrophysiological activity of the ion channels over the cells is an essential part of screening potential drug applicants. Patch clamping may be the standard technique for ion channel assay and it is typically a laborious and skill-intensive process that limitations the throughput of electrophysiology measurement, which really is a bottleneck for drug discovery process. We are currently working with our sector counterparts to consider this project to another level.